Year : 2022

Volume : Volume 13

Issue : Issue 6

Address for correspondence :
Manisha Gaurav
manishagaurav22@gmail.com

Abstract

Background: Trigeminal neuralgia (TN) is a clinical condition characterized by a sudden, usually unilateral, brief, stabbing, and recurrent pain with a distribution consistent with one or more divisions of 5th cranial nerve. The guidelines on pharmaceutical TN management published by the American Academy of Neurology and the European Federation of Neurological Societies recommend Carbamazepine (CBZ; 200–1200 mg/day) as first-line therapy. Objective: The objective of this study was to study the role of CBZ in the treatment of TN. Methods: The study was carried out in the department of Oral Medicine and Radiology of Patna Dental College and Hospital with patient informed consent. Four hundred and thirty-eight patients (265 males and 173 females) were examined with various complaints among which 14 (four males and ten females) of them presented with classical TN who had treatment with CBZ. Results: In this study, the prevalence of TN was 19 % among total number of patients selected. Out of the 14 patients suffering with TN, ten of them were full responders to CBZ, three of them responded partially, and remaining one was non-responder. Conclusion: In our study, we found that classic TN was most common in age group of 45–60 years with female predominance. It also shows that majority of patients of TN show satisfactory and adequate relief from CBZ.

Keywords: Carbamazepine, Non-responders, Partial responders, Responders, Trigeminal neuralgia.